AAP
ANIP icon

Ardsley Advisory Partners’s ANI Pharmaceuticals ANIP Stock Holding History

Ardsley Advisory Partners’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-45,000
Closed -$2.51M – 161
2016
Q2 		$2.51M Buy
+45,000
New +$2.19M 0.44% 55

Other funds holding ANIP

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return

Ardsley Advisory Partners's ANIP Position: Q3 2016 in Review

Ardsley Advisory Partners sold out of ANI Pharmaceuticals (ANIP) in Q3 2016, closing a stake of 45,000 shares — an estimated $2.51M sold.

Ardsley Advisory Partners first reported a position in ANIP in Q2 2016 and held it in 1 quarter. The position peaked at $2.51M in Q2 2016. 171 funds tracked by Wall St. Rank hold ANIP as of Q3 2016.

  • Ardsley Advisory Partners reported no remaining ANI Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Ardsley Advisory Partners sold 45,000 ANI Pharmaceuticals shares in Q3 2016, an estimated $2.51M.
  • Ardsley Advisory Partners first reported a position in ANI Pharmaceuticals in Q2 2016 and held it in 1 quarter.
  • Ardsley Advisory Partners's ANI Pharmaceuticals position peaked at $2.51M in Q2 2016.
  • 171 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2016.

Based on Ardsley Advisory Partners's 13F filing for Q3 2016, filed 14 Nov 2016.